Modern management of Cardiometabolic continuum: from overweight/obesity to prediabetes/type 2 diabetes mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00084971" target="_blank" >RIV/00023001:_____/24:00084971 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/24:10481952 RIV/00669806:_____/24:10481952

Výsledek na webu

<a href="https://link.springer.com/content/pdf/10.1007/s13300-024-01615-5.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007/s13300-024-01615-5.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s13300-024-01615-5" target="_blank" >10.1007/s13300-024-01615-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Modern management of Cardiometabolic continuum: from overweight/obesity to prediabetes/type 2 diabetes mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group

Popis výsledku v původním jazyce

The increasing global incidence of obesity and type 2 diabetes mellitus (T2D) underscores the urgency of addressing these interconnected health challenges. Obesity enhances genetic and environmental influences on T2D, being not only a primary risk factor but also exacerbating its severity. The complex mechanisms linking obesity and T2D involve adiposity-driven changes in beta-cell function, adipose tissue functioning, and multi-organ insulin resistance (IR). Early detection and tailored treatment of T2D and obesity are crucial to mitigate future complications. Moreover, personalized and early intensified therapy considering the presence of comorbidities can delay disease progression and diminish the risk of cardiorenal complications. Employing combination therapies and embracing a disease-modifying strategy are paramount. Clinical trials provide evidence confirming the efficacy and safety of glucagon-like peptide 1 receptor agonists (GLP-1 RAs). Their use is associated with substantial and durable body weight reduction, exceeding 15%, and improved glucose control which further translate into T2D prevention, possible disease remission, and improvement of cardiometabolic risk factors and associated complications. Therefore, on the basis of clinical experience and current evidence, the Eastern and Southern Europe Diabetes and Obesity Expert Group recommends a personalized, polymodal approach (comprising GLP-1 RAs) tailored to individual patient&apos;s disease phenotype to optimize diabetes and obesity therapy. We also expect that the increasing availability of dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists will significantly contribute to the modern management of the cardiometabolic continuum.

Název v anglickém jazyce

Modern management of Cardiometabolic continuum: from overweight/obesity to prediabetes/type 2 diabetes mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group

Popis výsledku anglicky

The increasing global incidence of obesity and type 2 diabetes mellitus (T2D) underscores the urgency of addressing these interconnected health challenges. Obesity enhances genetic and environmental influences on T2D, being not only a primary risk factor but also exacerbating its severity. The complex mechanisms linking obesity and T2D involve adiposity-driven changes in beta-cell function, adipose tissue functioning, and multi-organ insulin resistance (IR). Early detection and tailored treatment of T2D and obesity are crucial to mitigate future complications. Moreover, personalized and early intensified therapy considering the presence of comorbidities can delay disease progression and diminish the risk of cardiorenal complications. Employing combination therapies and embracing a disease-modifying strategy are paramount. Clinical trials provide evidence confirming the efficacy and safety of glucagon-like peptide 1 receptor agonists (GLP-1 RAs). Their use is associated with substantial and durable body weight reduction, exceeding 15%, and improved glucose control which further translate into T2D prevention, possible disease remission, and improvement of cardiometabolic risk factors and associated complications. Therefore, on the basis of clinical experience and current evidence, the Eastern and Southern Europe Diabetes and Obesity Expert Group recommends a personalized, polymodal approach (comprising GLP-1 RAs) tailored to individual patient&apos;s disease phenotype to optimize diabetes and obesity therapy. We also expect that the increasing availability of dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists will significantly contribute to the modern management of the cardiometabolic continuum.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes therapy

ISSN

1869-6953

e-ISSN

1869-6961

Svazek periodika

15

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

28

Strana od-do

1865-1892

Kód UT WoS článku

001269540300001

EID výsledku v databázi Scopus

2-s2.0-85198103917